Professional Documents
Culture Documents
A R T I C L E I N F O A B S T R A C T
Keywords: Background: Transfusion-transmitted infectious diseases remain a major concern for blood safety, particularly
Cobas MPX with hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Nucleic acid
Blood donor screening testing (NAT) in donor screening shortens the serologically negative window period and reduces virus trans-
Occult HBV infection mission. The cobas MPX (Roche Molecular Systems, Inc., Branchburg, New Jersey) is a recently developed
Multiplex PCR
multiplex qualitative PCR system that enables the simultaneous detection of HBV, HCV, and HIV with improved
sensitivity and throughput using cobas 6800 and 8800 instruments.
Objectives: The aim of this study was to conduct an evaluation of the clinical sensitivity and specificity of cobas
MPX detection of HBV, HCV, and HIV in clinical specimens.
Study design: Among samples referred for HBV, HCV, and HIV-1 quantification at Severance Hospital, Yonsei
University College of Medicine, positive samples were selected to evaluate sensitivity. A total of 843 samples was
tested using both cobas MPX and COBAS AmpliPrep/COBAS TaqMan Tests for HBV, HCV, and HIV-1 using the
cobas 8800 system and a COBAS TaqMan 96 analyzer, respectively. Samples that showed discrepancies were
confirmed by nested PCR.
Conclusions: The cobas MPX achieved excellent sensitivity and specificity for the detection of HBV, HCV, and
HIV-1 in clinical samples. We found that the lower limit of detection (LOD) of blood screening by NAT actually
improves clinical sensitivity, and occult HBV infection prevalence among healthy employees of the hospital was
rather high.
⁎
Corresponding author.
E-mail addresses: KIMHS54@yuhs.ac, kimhs54@gmail.com (H.-S. Kim).
http://dx.doi.org/10.1016/j.jcv.2017.09.010
Received 6 March 2017; Received in revised form 13 August 2017; Accepted 18 September 2017
1386-6532/ © 2017 Elsevier B.V. All rights reserved.
J. Ha et al. Journal of Clinical Virology 96 (2017) 60–63
Table 1 (Plasmid #65459); this was a gift from Wang-Shick Ryu and had a
Claimed limit of detection by Probit analysis at a 95% hit rate for HIV, HCV, and HBV for known concentration [7]. The LOD of the assay was determined by
COBAS AmpliPrep/COBAS TaqMan Test, cobas MPX, and previous versions.
serially diluting the standard plasmid. DNA for the nested PCR was re-
Limit of detection, IU/mL extracted using a QIAamp Viral-RNA Mini Kit (Qiagen Inc., Valencia,
CA) according to the manufacturer's instructions.
HIV-1 HCV HBV
Table 2
Clinical sensitivity and specificity of cobas MPX.
Resultsa Total tested MPX results Clinical Sensitivity (%) 95% CI Clinical Specificity (%) 95% CI
61
J. Ha et al. Journal of Clinical Virology 96 (2017) 60–63
Table 3
Serologic status of the subjects with suspected occult HBV infection.
Case No. Sex Age HBsAg Anti-HBc Anti-HBs Cobas MPX Nested PCR and Sequencing
96.7–98.8) and 0.96 (95% CI, 0.94–0.98, P < 0.0001), respectively. absence of liver disease in Korea [9–12] (Table 4). Because anti-HBc has
HCV and HIV-1 testing showed a concordance rate of 100% (843/843, been considered as a marker of previous HBV exposure, many studies
95% CI 99.6–100.00) with kappa coefficient of 1.0. HBV testing showed performed HBV DNA tests on anti-HBc positive subjects to investigate
a concordance rate of 98.0% (826/843, 95% CI 96.8–98.8) with kappa the prevalence of OBI. However, Song et al. reported that anti-HBc was
coefficient of 0.91 (95% CI, 0.87–0.95, P < 0.0001). positive in only 27% of OBI cases in Korean adult subjects [11]. In this
study, anti-HBc was detected in almost half of the samples (6/15,
4.4. Serological assays for occult HBV infection samples 40.0%). Therefore, we reviewed literature that investigated OBI pre-
valence regardless of anti-HBc. Overall, 17–67% of OBI cases from the
Among the 510 samples from healthy employees, anti-HBs were literature were anti-HBc positive, not counting the extremes. Interest-
detected in 307 (60.2%). Among 17 HBV positive samples by the cobas ingly, the prevalence of OBI varied considerably from study to study.
MPX, HBsAg was negative for all samples. Anti-HBc and anti-HBs were Kim et al. detected 31 (16%) OBI cases from 195 outpatients of a gas-
detected in 6 (35.3%) and 11 (64.7%) samples, respectively (Table 3). trointestinal clinic with normal ALT levels. However, Song et al. re-
ported only 0.7% (7/1047) OBI prevalence for medical check-up sam-
5. Discussion ples. Various OBI prevalences were reported in Korea (Table 4). These
considerable differences in OBI prevalences could be explained mainly
This study found that the lower LOD of blood screening by NAT by the characteristics of the subjects. The different OBI prevalences of
actually improves clinical sensitivity. Molecular study of healthy em- same population in a study were resulted from the analytical sensitivity
ployee samples using the COBAS AmpliPrep/COBAS TaqMan test de- of HBV DNA detection methods [10,12]. Despite similar analytical
tected no positive samples. On the contrary, using cobas MPX, 17 po- sensitivity, OBI prevalence in this study was four-times higher than that
sitive samples were detected. This implies that occult HBV infection was reported by Song et al. (2.9 vs. 0.7%) [11]. This difference is
(OBI) could be better screened using cobas MPX by lowering the LOD in consistent with other studies, which concluded that the risk of con-
endemic areas. Among 17 positive samples by cobas MPX, 15 were tracting HBV by health care workers is four-times greater than that of
confirmed to be HBV positive by nested PCR and subsequent sequen- the general adult population [13,14].
cing. The remaining two samples showed no bands in nested PCR In conclusion, the cobas MPX test achieved excellent sensitivity and
analysis. However, although we used nested PCR as a confirmatory test, specificity for the detection of HBV, HCV, and HIV-1. We found that the
there is a possibility that the cobas MPX test has a lower LOD than lower LOD of NAT blood screening actually improves clinical sensi-
nested PCR. In our study, LOD of the nested PCR performed in the study tivity. Using the cobas MPX test, OBI was detected in 2.9% (15/510) of
was between 100-101 copies/mL and the claimed LOD of cobas MPX healthy hospital employees. The excellent clinical sensitivity and spe-
was 1.4 IU/mL (8.1 copies/mL under conversion factor of 5.82) [6]. cificity was accompanied by improved efficiency and reduction of the
Considering that the true results of the two discrepant samples showing costs and turn-around time of NAT for donor screening.
discrepancy remain unclear, the cobas MPX showed excellent clinical
sensitivity and specificity.
Whereas OBI infectivity depends on recipient immune status, blood Competing interests
taken from donors with OBI was shown to be potentially infectious, and
the risk is increased when large volumes of plasma are transfused [8]. No potential conflicts of interest relevant to this article were re-
In HBV endemic areas, the residual risk of transfusion-transmitted HBV ported.
infection originates from HBsAg-negative donors with OBI [1]. In this
study, the cobas MPX test detected HBV in 17 samples from healthy
workers, of which 15 samples were also confirmed by nested PCR and Funding
subsequent sequencing. When these 15 positive samples were con-
sidered as OBIs, the prevalence of OBI among the tested subjects was This research received no specific grant from any funding agency in
2.9% (15/510). the public, commercial, or not-for-profit sectors.
We reviewed literature that investigated OBI prevalence in the
62
J. Ha et al. Journal of Clinical Virology 96 (2017) 60–63
Ethical approval
55% (17/31)
70% (16/23)
65% (11/17)
100% (1/1)
75% (6/8)
86% (6/7)
67% (2/3)
Anti-HBs
This study was approved by Severance Hospital IRB (IRB No. 1-
2015-0047, Protocol No. RSS-MD-15-01).
References
52% (16/31)
17% (4/23)
53% (6/17)
100% (1/1)
29% (2/7)
67% (2/3)
0% (0/8)
Anti-HBc
[1] J.P. Allain, Occult hepatitis B virus infection: implications in transfusion, Vox Sang.
86 (2004) 83–91.
[2] P.F. Lindholm, K. Annen, G. Ramsey, Approaches to minimize infection risk in
blood banking and transfusion practice, Infect. Disord. Drug Targets 11 (2011)
45–56.
Analytical sensitivity (IU/mL)
[3] J.T. Wang, T.H. Wang, J.C. Sheu, L.N. Shih, J.T. Lin, D.S. Chen, Detection of he-
patitis B virus DNA by polymerase chain reaction in plasma of volunteer blood
donors negative for hepatitis B surface antigen, J. Infect. Dis. 163 (1991) 397–399.
[4] Roche, cobas® TaqScreen MPX Test: instruction manual, Roche Molecular Systems,
Inc., Branchburg, New Jersey, 2012.
[5] Roche, cobas® TaqScreen MPX Test version 2.0: instruction manual, Roche
Molecular Systems, Inc., Branchburg, New Jersey, 2014.
[6] Roche, cobas® MPX, Roche Molecular Systems, Inc., Branchburg New Jersey, 2015.
0.5−5.4
[7] H. Wang, S. Kim, W.S. Ryu, DDX3 DEAD-Box RNA helicase inhibits hepatitis B virus
73.2
3.8
1.4
60
24
5815–5824.
[8] J.P. Allain, I. Mihaljevic, M.I. Gonzalez-Fraile, K. Gubbe, L. Holm-Harritshoj,
J.M. Garcia, et al., Infectivity of blood products from donors with occult hepatitis B
COBAS Amplicor HBV Monitor test
TaqMan PCR
Nested PCR
Cobas MPX
[11] E.Y. Song, Y.M. Yun, M.H. Park, D.H. Seo, Prevalence of occult hepatitis B virus
infection in a general adult population in Korea, Intervirology 52 (2009) 57–62.
Method
[12] J.H. Yoo, S.G. Hwang, D.H. Yang, M.S. Son, C.-I. Kwon, K.H. Ko, S.P. Hong,
P.W. Park, K.S. Rim, Prevalence of occult hepatitis B virus infection in hemodialysis
patients, Korean J. Gastroenterol. 61 (2013) 209–214.
[13] L.A. Ciorlia, D.M. Zanetta, Hepatitis B in healthcare workers: prevalence, vaccina-
Age-years (range)
tion and relation to occupational factors, Brazilian J. Infect. Dis. 9 (2005) 384–389.
[14] E.B. Byrne, Viral hepatitis: an occupational hazard of medical personnel. Experience
of the Yalenew Haven Hospital, 1952–1965, JAMA 195 (1966) 362–364.
54 (15–94)
42 (14–72)
58 (25–86)
58 (25–86)
40 (23–67)
[15] Roche, COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0: instruction
manual, Roche Molecular Systems, Inc., Branchburg, New Jersey, 2016.
[16] Roche, COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, version 2.0: instruction
30.8
30.8
Hemodialysis patients
Hemodialysis patients
Medical check-up
Pregnant women
Pregnant women
Subjects
11.4% (23/202)
OBI prevalence
0.7% (7/1047)
2.9% (15/510)
16% (31/195)
3.2% (3/94)
1.1% (1/94)
4% (8/202)
Present study
Table 4
63